FIG. 1


Vehicle qdx1 IV
Conjugate 1, 0.30/0.013 mg/kg, qdx1 IV
Conjugate 1, 0.30/0.013 mg/kg, qdx1 IV + Trastuzumab, 3 mg/kg, qdx1 IP
Conjugate 1, 0.30/0.013 mg/kg, qdx1 IV + Trastuzumab, 10 mg/kg qdx1 IP
Conjugate 2, 0.30/0.011, mg/kg qdx1 IV + Trastuzumab, 10 mg/kg qdx1 IP
Conjugate 1, 0.30/0.013 mg/kg, qwx3 IV
Conjugate 1, 0.30/0.013 mg/kg, qwx3 IV + Trastuzumab, 3 mg/kg qwx3 IP
Conjugate 1, 0.30/0.013 mg/kg, qwx3 IV + Trastuzumab, 10 mg/kg qwx3 IP
Conjugate 2, 0.30/0.011 mg/kg, qwx3 IV + Trastuzumab, 10 mg/kg qwx3 IP
Trastuzumab, 10 mg/kg, qwx3 IP
Mean Tumor Volume ±SEM (mm³)
1000
800
600
400
200
0
1
1
8
15
0
7
14
21
28
35
42
49
56
63
70
77
Days on Study

FIG. 2


Vehicle, qdx1 IV
Conjugate 1, 3.0/0.13 mg/kg, qdx1 IV
Conjugate 2, 3.0/0.11 mg/kg, qdx1 IV + Trastuzumab, 10 mg/kg, qdx1 IP
Conjugate 2, 3.0/0.11 mg/kg, qdx1 IV + Pertuzumab, 10 mg/kg, qdx1 IP
Conjugate 1, 3.0/0.13 mg/kg, qdx1 IV + Trastuzumab, 3 mg/kg, qdx1 IP
Conjugate 1, 3.0/0.13 mg/kg, qdx1 IV + Trastuzumab, 10 mg/kg, qdx1 IP
Conjugate 1, 3.0/0.13 mg/kg, qdx1 IV + Pertuzumab, 3.mg/kg, qdx1 IP
Conjugate 1, 3.0/0.13 mg/kg, qdx1 IV + Pertuzumab, 10 mg/kg, qdx1 IP
Conjugate 2, 3.0/0.11 mg/kg, qdx1 IV + Trastuzumab, 3 mg/kg, qdx1 IP + Pertuzumab, 3 mg/kg, qdx1 IP
Conjugate 1, 3.0/0.13 mg/kg, qdx1 IV + Trastuzumab, 3 mg/kg, qdx1 IP + Pertuzumab, 3 mg/kg, qdx1 IP
Conjugte 1, 0.30/0.013 mg/kg, qwx3 IV
Conjugate 2, 0.30/ 0.011 mg/kg, qwx3 IV + Trastuzumab, 3 mg/kg, qwx3 IP
Conjugate 2, 0.30/0.011 mg/kg, qwx3 IV + Pertuzumab, 3.mg/kg, qwx3 IP
Conjugate 1, 0.30/0.013 mg/kg, qwx3 IV + Trastuzumab, 3 mg/kg, qwx3 IP
Conjugate 1, 0.30/0.013 mg/kg, qwx3 IV + Pertuzumab, 3 mg/k, qwx3 IP
Mean Tumor Volume ±SEM (mm³)
1000
750
500
250
0
0 7 14 21 28 35 42 49 56 63 70 77 84 91
Days on Study
1
1 8 15

FIG. 3


Vehicle, qdx1 IV
Conjugate 1, 0.20/0.007 mg/kg, qdx1 IV
Trastuzumab, 2 mg/kg, qdx1 IP
Pertuzumab, 2 mg/kg, qdx1 IP
Conjugate 2, 0.20/0.007 mg/kg, qdx1 IP
Conjugate 1, 0.20/0.007 mg/kg, qdx1 IV + Trastuzumab, 2 mg/kg, qdx1 IP
Conjugate 1, 0.20/0.007 mg/kg, qdx1 IV + Pertuzumab, 2 mg/kg, qdx1 IP
Trastuzumab, 2 mg/kg, qdx1 IP + Pertuzumab, 2 mg/kg, qdx1 IP
Conjugate 1, 0.20/0.007 mg/kg, qdx1 IV + Trastuzumab, 2 mg/kg, qdx1 IP + Pertuzumab, 2 mg/kg, qdx1 IP
Conjugate 1, 0.10/0.004 mg/kg, qwx3 IV
Conjugate 2, 0.10/0.004 mg/kg, qwx3 IV
Conjugate 1, 0.10/0.004 mg/kg, qwx3 IV + Trastuzumab, 2 mg/kg qdx1 IP
Conjugate 1, 0.10/0.004 mg/kg, qwx3 IV + Pertuzumab, 2 mg/kg qdx1 IP
Mean Tumor Volume +/- SEM (mm³)
1200
800
400
0
0
7
14
21
28
35
42
49
56
63
Days on Study
1
8
15

FIG. 4


Vehicle, qdx1 IV
Conjugate 2, 1.00 / 0.037 mg/kg
Conjugate 1, 1.00 / 0.043 mg/kg, qdx1 IV
Enhertu 1.00 / 0.026 mg/kg, qwx2 IV
Enhertu 3.00 / 0.078 mg/kg, qwx2 IV
Enhertu 10.00 / 0.261 mg/kg, qwx2 IV
Conjugate 1, 1.00 / 0.043 mg/kg, qdx1 IV + Enhertu 1.00 / 0.026 mg/kg, qwx2 IV
Conjugate 1, 1.00 / 0.043 mg/kg, qdx1 IV + Enhertu 3.00 / 0.078 mg/kg, qwx2 IV
Conjugate 1, 1.00 / 0.043 mg/kg, qdx1 IV + Enhertu 10.00 / 0.261 mg/kg, qwx2 IV
Conjugate 1, 0.30 / 0.013 mg/kg, qwx2 IV
Conjugate 1, 0.30 / 0.013 mg/kg, qwx2 IV + Enhertu 1.00 / 0.026 mg/kg, qwx2 IV
Conjugate 1, 0.30 / 0.013 mg/kg, qwx2 IV + Enhertu 3.00 / 0.026 mg/kg, qwx2 IV
Conjugate 1, 0.30 / 0.013 mg/kg, qwx2 IV + Enhertu 10.00 / 0.261 mg/kg, qwx2 IV
Mean Tumor Volume ±SEM (mm³)
1200
900
600
300
0
0 7 14 21 28 35 42 49 56 63
Days on Study
1
1
8

FIG. 5


Vehicle, qdx1 IV
Conjugate 3, 0.30/0.013 mg/kg, qdx1 IV
Conjugate 3, 1.0/0.040 mg/kg qdx1 IV
Conjugate 3, 3.0/0.12 mg/kg, qdx1 IV
Conjugate 4, 0.30/0.012 mg/kg, qdx1 IV
Conjugate 4, 1.0/0.035 mg/kg, qdx1 IV
Conjugate 4, 3.0/0.10 mg/kg, qdx1 IV
anti-PD-1 RMP1-14, 1 mg/kg biwx2, IP
anti-PD-1 RMP1-14, 5 mg/kg, biwx2 IP
Conjugate 3, 0.30/0.012 mg/kg, qdx1 IV + anti-PD-1 RMP1-14, 5 mg/kg, biwx2 IP
Conjugate 3, 1.0/0.035 mg/kg, qdx1 IV + anti-PD-1 RMP1-14, 5 mg/kg, biwx2 IP
Conjugate 4, 0.30/0.012 mg/kg, qdx1 IV + anti-PD-1 RMP1-14, 5 mg/kg, biwx2 IP
Conjugate 4, 1.0/0.035 mg/kg, qdx1 IV + anti-PD1 RMP1-14, 5 mg/kg, biwx2 IP
Mean Tumor Volume ±SEM (mm³)
1800
1200
600
0
0 1 7 14 21 28 35 42
Days on Study
1 4 8 11

FIG. 6A



FIG. 6B



FIG. 6C



FIG. 6D



FIG. 7


PD-L1
Human
Normalized mRNA Counts
800
600
400
200
0
Vehicle
Control ADC
Conjugate 1
PD-L1
Mouse
Normalized mRNA Counts
6000
4000
2000
0
Vehicle
Control ADC
Conjugate 1